СРАВНИТЕЛЬНЫЙ АНАЛИЗ ЭФФЕКТИВНОСТИ ТЕРАПИИ БОЛЕЗНИ ПАРКИНСОНА

Συγγραφείς: Раимова , М.М., Сафаров, Ш.Ш.

Πηγή: Natural Sciences in the modern world: theoretical and practical research; Vol. 4 No. 11 (2025): Natural Sciences in the modern world: theoretical and practical research; 90-92 ; Естественные науки в современном мире: теоретические и практические исследования; Том 4 № 11 (2025): Естественные науки в современном мире: теоретические и практические исследования; 90-92 ; 2181-2020

Θεματικοί όροι: Болезнь Паркинсона, дофаминергическая терапия, леводопа, амантадина сульфат (ПК-Мерц), NMDA-рецепторы, эффективность терапии, UPDRS, шкала Хен и Яра, шкала Шваба и Ингланда, лекарственные дискинезии, моторные флуктуации

Περιγραφή αρχείου: application/pdf

Relation: https://in-academy.uz/index.php/zdtf/article/view/60511/38059

Διαθεσιμότητα: https://in-academy.uz/index.php/zdtf/article/view/60511

Apathy in Parkinson's disease patients ; Апатия при болезни Паркинсона

Συγγραφείς: M. R. Nodel, М. Р. Нодель

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 6, No 1 (2014); 80-84 ; Неврология, нейропсихиатрия, психосоматика; Vol 6, No 1 (2014); 80-84 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2014-1

Θεματικοί όροι: прамипексол, apathy, pathophysiology, dopaminergic therapy, pramipexole, апатия, патофизиология, дофаминергическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/378/377; Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinsons disease. Mov Disord. 2009; 24(15):2175–86. DOI:10.1002/mds.22589.; Scaravilli T, Gasparoli E, Rinaldi F, et al. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci. 2003 Oct;24(3):209–10. DOI: http://dx.doi.org/10.1007/s10072-003-0134-y.; Gallanger DA, Lees AJ, Shrag A. What are the most important nonmotor symptoms in patients with Parkinsons disease and are we missing them? Mov Disord. 2010;15(15):2493–500. DOI:10.1002/mds.23394.; Нодель МР, Яхно НН. Нервно-психические нарушения болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2009;(2):3–8. [Nodel' MR, Yakhno NN. Nervous and mental disorders of parkinson's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;(2):3–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2009-30.; Левин ОС. Болезнь Паркинсона как нейропсихиатрическое заболевание. Руководство для врачей по материалам II Национального конгресса по болезни Паркинсона и расстройствам движений. Под. ред. С.Н. Иллариошкина, О.С. Левина. Москва: НЦН РАМН; 2011. C. 99–104. [Levin OS. Bolezn' Parkinsona kak neiropsikhiatricheskoe zabolevanie. Rukovodstvo dlya vrachei po materialam II Natsional'nogo kongressa po bolezni Parkinsona i rasstroistvam dvizhenii [Parkinson's illness as neuropsychiatric disease. The management for doctors on materials II of the National congress due to illness Parkinson and to disorders of movements]. Illarioshkina SN, Levina OS, editors. Moscow: NTsN RAMN; 2011. P. 99–104.]; Вознесенская ТГ. Синдром апатии. Неврологический журнал. 2013;18(3):4–10. [Voznesenskaya TG. Аpathy syndrome. Nevrologicheskii zhurnal. 2013;18(3):4–10. (In Russ.)]; Levy R, Dubois B. Apathy and functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916–28. DOI: http://dx.doi.org/10.1093/cercor/bhj043. Epub 2005 Oct 5.; Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–62. DOI: http://dx.doi.org/10.1016/0165-1781(91)90040-V.; Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimers disease. J Neurol Neurosurg Psychiatr. 2006;77(1):8–11. DOI: http://dx.doi.org/10.1136/jnnp.2005.069575.; Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuroposychiatric disorders. Eur Psychiatry. 2009;24(2):98–104. DOI:10.1016/j.eurpsy.2008.09.001.; Epub 2009 Feb 7.; Sockeel P, Dujardin K, Devos D, et.al. The Lille apathy rating scale (LARS): a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77(5):579–84. DOI: http://dx.doi.org/10.1136/jnnp.2005.075929.; Starkstein SE, Mayberg HS, Preziosi TJ, et.al. Reliability, validity, and clinical correlates of apathy in Parkinsons disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–9.; Leroi I, David R, Robert PH. Apathy in Parkinsons disease. In: Psychiatry of in Parkinsons disease. Edmeier KP, O’Brien JT, Taylor J-P, editors. Basel: Karger; 2012. P. 27–40. DOI: http://dx.doi.org/10.1159/000331524.; Pedersen KF, Larsen JP, Alves G, Aarsland D. Prevalence and clinical correlates of apathy in Parkinsons disease: a community-based study. Parkinsonism Relat Disord. 2009 May;15(4):295–9. DOI:10.1016/j.parkreldis.2008.07.006.; Epub 2008 Sep 17.; Mulin E, Leone E, Dujardin K, et al. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry. 2011;26(2):158–65. DOI:10.1002/gps.2508.; Нодель МР, Яхно НН. Апатия при болезни Паркинсона. Неврологический журнал. 2014;1:9–15. [Nodel of MR, Yakhno NN. Apathy at Parkinson's illness. Nevrologicheskii zhurnal. 2014;1:9–15. (In Russ.)]; Bogart KR. Is apathy a valid and meaningful symptom or syndrome in Parkinsons disease? A critical review. Health Psychol. 2011;30(4):386–400. DOI:10.1037/a0022851.; Jordan LL, Zahodne LB, Okun MS, Bowers D. Hedonistic and behavioral deficits associated with apathy in Parkinsons disease: potential treatment implications. Mov Disord. 2013;28(9):1301–04. DOI:10.1002/mds.25496. Epub 2013 May 27.; Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):636–42. DOI: http://dx.doi.org/10.1136/jnnp.73.6.636.; Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23(7):964–9. DOI:10.1002/mds.21949.; Robbins T, Evritt B. Neurobehavioral mechanism of reward and motivation.; Curr Opin Neurobiol. 1996;6(2):228–36. DOI: http://dx.doi.org/10.1016/S0959-4388(96)80077-8.; Reijnders JS, Scholtissen B, Weber WE, et al. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxed-based morphometry. Mov Disord. 2010;25(14):2318–25. DOI:10.1002/mds.23268. 23. Starkstein SE, Federoff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke. 1993:24(11):1625–30. DOI: http://dx.doi.org/10.1161/01.STR.24.11.1625.; Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatr Clin Neuroscie.1998;10(3):314–9.; Reijnders J, Ehrt U, Lousberg R, et al. The association between motor subtypes and psychopatology in Parkinsons disease. Parkinsonism Relat Disord. 2009;15(5):379–82. DOI:10.1016/j.parkreldis.2008.09.003. Epub 2008 Oct 31.; Pedersen KF, Alves G, Aarsland D, et al. Occurence and risk factors for apathy in Parkinsons disease:a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2009;80(11):1279–82. DOI:10.1136/jnnp.2008.170043.; Нодель МР, Русакова ИМ, Яхно НН. Клиническая оценка нарушений сна и бодрствования при болезни Паркинсона. Неврологический журнал. 2010;(2):19–25. [Nodel' MR, Rusakova IM, Yakhno NN. Clinical assessment of violations of a dream and wakefulness at Parkinson's illness. Nevrologicheskii zhurnal. 2010;(2):19–25. (In Russ.)]; Vendette M, Gagnon JF, Decary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology. 2007;69(19):1843–9. DOI: http://dx.doi.org/10.1212/01.wnl. 0000278114.14096.74.; Narabayashi H. Akinesia in parkinsonism. In: Movement disorders in Neurology and neuropsychiatry. Joseph AB, Young RR, editors. Oxford: Blackwell Science; 1999. P. 185–8.; Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical psychiatry: an update. J Psychosom Res. 2002;53(20:647–54.; Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinsons disease. Mov Disord. 2009;24(16):2391–7. DOI:10.1002/mds.22843.; Barone P, Antonini A, Colosimo C, et al. The Priamo Study : a multicenter assessement of nonmotor symptoms and their impact on quality of life in Parkinsons disease. Mov Disord. 2009;11(24):1641–9. DOI: http://dx.doi.org/10.1002/mds.23872.; Benito-Leon J, Cubo E, Coronell C, et al. Impact of apathy on health-related quality of life in recently diagnosed Parkinsons disease: the ANIMO study. Mov Disord. 2012;27(2):211–8. DOI:10.1002/mds.23872. Epub 2011 Jul 20.; Mc Kinlay A, Grace RC, Dalrymple-Alford JC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinsons disease. Parkinsonism Relat Disord. 2008;14(1):37–42. DOI: http://dx.doi.org/10.1016/j.parkreldis.2007.05.009. Epub 2007 Jul 12; Wangpakaran N, van Reekum R, Wangpakaran T, Clarke D. Selective serotonine reuptake ingibitor use associates with apathy among depressed elderly: a case control study. Ann Gen Psychiatry. 2007;6:7. DOI: http://dx.doi.org/10.1186/1744-859X-6-7.; Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinsons disease and dementia with Lewy bodies. J Geriatr Psychiatry. 2000;15(5):387–92.; Campbell JJ, Duffy JD. Treatment strategies in amotivated patients. Psychiatry Ann. 1997;27:44–9.; Czernecki V, Schupbach M, Levy R, et al. Apathy following subthalamic nucleus stimulation in Parkinsons disease is improved by treatment with a dopaminergic agonist. Mov Disord. 2006;21:652.; Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136 (Pt 5):1568–77. DOI:10.1093/brain/awt067. Epub 2013 Mar 29.; Leentjens A, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivotional symptoms in Parkinson disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89–92. DOI:10.1016/j.clinthera.2009.01.012.; Нодель МР, Яхно НН. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(5):32–8. [Nodel MR, Yakhno NN. Mirapex (pramipexole) in the treatment of nonmotor disturbances in Parkinson's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(5):32–8. (In Russ.)]

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/378
https://doi.org/10.14412/2074-2711-2014-1-80-84

АПАТИЯ ПРИ БОЛЕЗНИ ПАРКИНСОНА

Συγγραφείς: Нодель, Марина

Θεματικοί όροι: БОЛЕЗНЬ ПАРКИНСОНА, АПАТИЯ, ПАТОФИЗИОЛОГИЯ, ДОФАМИНЕРГИЧЕСКАЯ ТЕРАПИЯ, ПРАМИПЕКСОЛ, PARKINSON''S DISEASE

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/apatiya-pri-bolezni-parkinsona
http://cyberleninka.ru/article_covers/15577341.png

ДОФАМИНОВЫЙ ДИЗРЕГУЛЯЦИОННЫЙ СИНДРОМ ПРИ БОЛЕЗНИ ПАРКИНСОНА

Συγγραφείς: Никитина, А., Федорова, Наталия

Θεματικοί όροι: БОЛЕЗНЬ ПАРКИНСОНА, ДОФАМИНОВЫЙ ДИЗРЕГУЛЯЦИОННЫЙ СИНДРОМ, ДОФАМИНЕРГИЧЕСКАЯ ТЕРАПИЯ, PARKINSON’S DISEASE

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/dofaminovyy-dizregulyatsionnyy-sindrom-pri-bolezni-parkinsona
http://cyberleninka.ru/article_covers/14470597.png

Апатия при болезни Паркинсона

Πηγή: Неврология, нейропсихиатрия, психосоматика.

Θεματικοί όροι: БОЛЕЗНЬ ПАРКИНСОНА, АПАТИЯ, ПАТОФИЗИОЛОГИЯ, ДОФАМИНЕРГИЧЕСКАЯ ТЕРАПИЯ, ПРАМИПЕКСОЛ, PARKINSON'S DISEASE

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/apatiya-pri-bolezni-parkinsona
http://cyberleninka.ru/article_covers/15577341.png

Дофаминовый дизрегуляционный синдром при болезни Паркинсона

Πηγή: Неврология, нейропсихиатрия, психосоматика.

Θεματικοί όροι: БОЛЕЗНЬ ПАРКИНСОНА, ДОФАМИНОВЫЙ ДИЗРЕГУЛЯЦИОННЫЙ СИНДРОМ, ДОФАМИНЕРГИЧЕСКАЯ ТЕРАПИЯ, PARKINSON'S DISEASE, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/14470597.png
http://cyberleninka.ru/article/n/dofaminovyy-dizregulyatsionnyy-sindrom-pri-bolezni-parkinsona